Manfred Schneider

Manfred joined Asceneuron in 2013 as an expert consultant in drug metabolism, pharmacokinetics and toxicology (ADME/PK/TOX) to guide optimization of drug-like properties in early stages of drug discovery as well as to support non-clinical (IND-enabling safety pharmacology & toxicology) and clinical bioanalytics and PKPD. He was instrumental in the early discovery of the clinical lead ASN120290 and its clinical development up to Phase 2.

Manfred has almost 20 years of international experience in his field and is board-certified toxicologist (US) since 2004. Between 2006 and 2012 he held positions as Head of DMPK & Toxicology at Addex Therapeutics and Head of early ADME at Merck Serono (Geneva, Switzerland). Prior to this he worked for 10 years in the United States at Forest Laboratories (New York City) and at Tularik (now Amgen; South San Francisco) following a toxicology postdoc at the University of California at Berkeley. In 1996 he received his PhD in Analytical Chemistry and Toxicology from the University of Ulm, Germany. Manfred is author of 19 peer-reviewed publications.